Anti-metapneumovirus monoclonal antibody - AstraZeneca
Alternative Names: Anti-hMPV MAb - Astrazeneca; mAb-338Latest Information Update: 05 Aug 2021
At a glance
- Originator ViroNovative
- Developer MedImmune
- Class Monoclonal antibodies; Viral vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metapneumovirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metapneumovirus-infections in USA (IM, Injection)
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in human metapneumovirus presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
- 18 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections pharmacodynamics and immunogenicity sections